| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | L3MBT; H-l(3)mbt-l |
| WB Predicted band size | 79 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human L3MBTL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于L3MBTL2抗体的3篇代表性文献及其摘要概括：
---
1. **"L3MBTL2 mediates silencing of repetitive DNA and regulates chromatin compaction"**
*Authors: Smith J, Doe R, Brown A (2018)*
摘要：该研究利用L3MBTL2特异性抗体进行染色质免疫沉淀(ChIP)实验，发现L3MBTL2通过识别组蛋白H4K20单甲基化修饰，靶向重复DNA区域并促进染色质凝缩，抑制转座元件和卫星序列的转录。
---
2. **"Structural basis for the interaction of L3MBTL2 with non-methylated histone peptides"**
*Authors: Chen X, Wang Y, Zhang L (2016)*
摘要：通过X射线晶体学结合抗体验证实验，揭示了L3MBTL2蛋白的MBT结构域与未甲基化组蛋白H3尾部结合的分子机制，表明其在基因沉默中可能通过竞争性抑制甲基化依赖的相互作用发挥作用。
---
3. **"Development and validation of a monoclonal antibody targeting the C-terminal domain of L3MBTL2"**
*Authors: Lee S, Kim T, Park H (2020)*
摘要：研究团队开发了一种靶向L3MBTL2 C端结构域的高效单克隆抗体，验证其在免疫荧光、Western blot和流式细胞术中的特异性，并应用于乳腺癌细胞中L3MBTL2亚细胞定位的动态分析。
---
4. **"L3MBTL2 depletion enhances somatic cell reprogramming through chromatin accessibility modulation"**
*Authors: García-Pérez R, Esteban-Cantos A, Rodríguez-Paredes M (2019)*
摘要：通过CRISPR/Cas9敲除和L3MBTL2抗体功能阻断实验，证明L3MBTL2通过维持异染色质稳定性抑制体细胞重编程，其缺失导致染色质开放性和多能性基因激活。
---
**备注**：以上文献信息为示例性内容，实际文献需通过PubMed或Google Scholar以关键词“L3MBTL2 antibody”或“L3MBTL2 function”检索获取。建议优先选择近5年发表于《Nature Structural & Molecular Biology》《Cell Reports》等期刊的研究。
L3MBTL2 (Lethal(3)malignant brain tumor-like 2) is a chromatin-associated protein belonging to the MBT (malignant brain tumor) domain-containing protein family, which is implicated in epigenetic regulation. It recognizes and binds to mono- or dimethylated lysine residues on histones (e.g., H4K20me1/2), a feature linked to transcriptional repression and chromatin compaction. L3MBTL2 functions as a transcriptional repressor, often acting in concert with polycomb repressive complexes (PRCs) or other chromatin modifiers to regulate gene expression, genomic stability, and cellular differentiation. Its role in suppressing inappropriate transcription has been associated with tumor suppression, as dysregulation of L3MBTL2 is observed in certain cancers.
Antibodies targeting L3MBTL2 are essential tools for studying its localization, interactions, and mechanistic roles in chromatin biology. They are widely used in techniques like Western blotting, immunoprecipitation (IP), chromatin immunoprecipitation (ChIP), and immunofluorescence to investigate its involvement in DNA repair, cell cycle regulation, and developmental processes. Commercially available L3MBTL2 antibodies are typically validated for specificity against its unique MBT domains or other epitopes, enabling researchers to distinguish it from related family members (e.g., L3MBTL1 or MBTD1). Studies using these antibodies have highlighted L3MBTL2's contribution to maintaining heterochromatin integrity and its potential as a biomarker or therapeutic target in diseases marked by epigenetic dysregulation.
×
